Covalent inhibitor reactivity prediction by the electrophilicity index—in and out of scope

被引:0
|
作者
Markus R. Hermann
Alexander Pautsch
Marc A. Grundl
Alexander Weber
Christofer S. Tautermann
机构
[1] Medicinal Chemistry,
[2] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
关键词
Compound reactivity; Covalent drug discovery; DFT;
D O I
暂无
中图分类号
学科分类号
摘要
Drug discovery is an expensive and time-consuming process. To make this process more efficient quantum chemistry methods can be employed. The electrophilicity index is one property that can be calculated by quantum chemistry methods, and if calculated correctly gives insight into the reactivity of covalent inhibitors. Herein we present the usage of the electrophilicity index on three common warheads, i.e., acrylamides, 2-chloroacetamides, and propargylamides. We thoroughly examine the properties of the electrophilicity index, show which pitfalls should be avoided, and what the requirements to successfully apply the electrophilicity index are.
引用
收藏
页码:531 / 539
页数:8
相关论文
共 35 条
  • [31] D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C: Human dose prediction and first-in-human (FIH) trial design.
    Lu, Jingtao
    Zhang, Jing
    Zheng, Zhiqiang
    Chen, Cheng
    Wang, Jia
    Chen, Janet
    Lu, Jiang
    Rui, Haopeng
    Wang, Allison
    Chen, Zhi Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
    Mamounas, Eleftherios P.
    Bandos, Hanna
    Rastogi, Priya
    Zhang, Yi
    Treuner, Kai
    Lucas, Peter C.
    Geyer, Charles E.
    Fehrenbacher, Louis
    Chia, Stephen K.
    Brufsky, Adam M.
    Walshe, Janice M.
    Soori, Gamini S.
    Dakhil, Shaker
    Paik, Soonmyung
    Swain, Sandra M.
    Sgroi, Dennis C.
    Schnabel, Catherine A.
    Wolmark, Norman
    CLINICAL CANCER RESEARCH, 2024, 30 (09) : 1984 - 1991
  • [33] Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR plus breast cancer: NRG oncology/NSABP B-42.
    Mamounas, Eleftherios P.
    Bandos, Hanna
    Rastogi, Priya
    Zhang, Yi
    Treuner, Kai
    Lucas, Peter C.
    Geyer, Charles E.
    Fehrenbacher, Louis
    Graham, Mark
    Chia, Stephen K. L.
    Brufsky, Adam
    Walshe, Janice Maria
    Soori, Gamini S.
    Dakhil, Shaker R.
    Paik, Soonmyung
    Swain, Sandra M.
    Sgroi, Dennis
    Schnabel, Catherine A.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Correction: Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC)
    Sang-Yun Lee
    Hyeong Jun Cho
    Jimin Choi
    Bosung Ku
    Seok Whan Moon
    Mi Hyoung Moon
    Kyung Soo Kim
    Kwanyong Hyun
    Tae-Jung Kim
    Yeoun Eun Sung
    Yongki Hwang
    Eunyoung Lee
    Dong Hyuck Ahn
    Joon Young Choi
    Jeong Uk Lim
    Chan Kwon Park
    Sung Won Kim
    Seung Joon Kim
    In-Seong Koo
    Woo Seok Jung
    Sang-Hyun Lee
    Chang Dong Yeo
    Dong Woo Lee
    Journal of Experimental & Clinical Cancer Research, 42
  • [35] Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC) (vol 42, 309, 2023)
    Lee, Sang-Yun
    Cho, Hyeong Jun
    Choi, Jimin
    Ku, Bosung
    Moon, Seok Whan
    Moon, Mi Hyoung
    Kim, Kyung Soo
    Hyun, Kwanyong
    Kim, Tae-Jung
    Sung, Yeoun Eun
    Hwang, Yongki
    Lee, Eunyoung
    Ahn, Dong Hyuck
    Choi, Joon Young
    Lim, Jeong Uk
    Park, Chan Kwon
    Kim, Sung Won
    Kim, Seung Joon
    Koo, In-Seong
    Jung, Woo Seok
    Lee, Sang-Hyun
    Yeo, Chang Dong
    Lee, Dong Woo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)